Importance Hypertrophic cardiomyopathy causes limiting symptoms in patients, mediated
partly through inefficient myocardial energy use. There is conflicting evidence for therapy
with inhibitors of myocardial fatty acid metabolism in patients with nonobstructive
hypertrophic cardiomyopathy. Objective To determine the effect of oral therapy with
trimetazidine, a direct inhibitor of fatty acid β-oxidation, on exercise capacity in patients with
symptomatic nonobstructive hypertrophic cardiomyopathy. Design, Setting, and Participants …